Investors might want to bet on Banco Santander (SAN) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individ ...

Core Insights - Tolebrutinib has shown positive results in delaying disability progression in patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS), a condition currently lacking approved treatment options [1][6] - The HERCULES phase 3 study results were published in the New England Journal of Medicine (NEJM) and presented at major neurology conferences, indicating a significant advancement in multiple sclerosis treatment [1][2] Tolebrutinib Efficacy - In the HERCULES study, tolebrutinib delayed the time to onset of 6-month confirmed disability progression (CDP) by 31% compared to placebo, with a hazard ratio of 0.69 and a p-value of 0.003 [3][6] - The GEMINI 1 and 2 studies did not demonstrate superiority in reducing annualized relapse rate (ARR) compared to teriflunomide, with ARR of 0.13 for tolebrutinib and 0.12 for teriflunomide in GEMINI 1, and 0.11 for both groups in GEMINI 2 [4][17] Safety Profile - Tolebrutinib was generally well-tolerated, with liver enzyme elevations observed in 4.0% of participants compared to 1.6% in the placebo group in the HERCULES study [5][7] - A small proportion (0.5%) of participants experienced significant ALT increases (>20xULN), all occurring within the first 90 days of treatment [5][7] Regulatory Status - Tolebrutinib is under priority review by the US FDA with a target action date of September 28, 2025, and a regulatory submission is also under review in the EU [6][8] - The drug has previously received breakthrough therapy designation from the FDA based on positive phase 3 study results [12] Mechanism of Action - Tolebrutinib is a Bruton's tyrosine kinase (BTK) inhibitor designed to target neuroinflammation behind the blood-brain barrier, addressing the underlying pathology of progressive multiple sclerosis [11][13] - This mechanism allows it to modulate both B-lymphocytes and disease-associated microglia, potentially transforming the treatment landscape for multiple sclerosis [11][13]

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,467,152,142Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry under nu ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies. These figures are just a handful of the metrics value investors tend to look at, but they help show that Banco Santander is likely being undervalued right now. Considering this, as well as the strength of its ear ...

Core Perspective - Qfitlia (fitusiran) has been approved by the US FDA as the first antithrombin-lowering therapy for the routine prophylaxis of hemophilia A and B, providing a significant advancement in treatment options for patients with or without inhibitors [1][10]. Company Insights - Sanofi emphasizes its commitment to innovation in the treatment of rare blood disorders, highlighting Qfitlia's potential to transform hemophilia care through effective bleed protection and reduced treatment burden [3]. - The company is launching HemAssist alongside Qfitlia to offer comprehensive patient support services, including insurance assistance and educational resources [9]. Industry Impact - Qfitlia's unique mechanism allows for the treatment of all types of hemophilia, including those with inhibitors, addressing significant unmet medical needs in the market [4]. - The ATLAS clinical development program has shown that Qfitlia can achieve a significant reduction in annualized bleeding rates (ABR) by 71% for patients without inhibitors and 73% for patients with inhibitors compared to traditional on-demand treatments [7][12]. Clinical Data - In the ATLAS studies, Qfitlia demonstrated low bleed rates with as few as six injections per year, with nearly half of patients experiencing one or fewer bleeds during the open-label extension study [7][12]. - The FDA has also approved the Siemens Healthineers' INNOVANCE Antithrombin assay as a companion diagnostic for Qfitlia, allowing for AT level measurement at no cost to patients [8].

watch nowThe White House's protectionist policies could hit the U.S. harder than Europe in the short term, Banco Santander's executive chair told CNBC on Thursday, as tariffs take a toll on domestic consumers."Tariffs [are] a tax. It's a tax on the consumer." Ana Botín said in an interview with CNBC's Karen Tso in Brussels on the sidelines of the 2025 IIF European Summit. "Ultimately, the economy will pay a price. There will be less growth and there will be more inflation, other things equal."President Dona ...

Core Viewpoint - The US FDA has granted fast track designation to Sanofi's mRNA vaccine candidate aimed at preventing chlamydia infection, highlighting its potential to address a significant public health need [1][2]. Group 1: Vaccine Development - The chlamydia vaccine candidate is designed to protect against primary genital tract infection and reinfection by Chlamydia trachomatis, with a phase 1/2 clinical study planned to evaluate its immunogenicity and safety in adults aged 18 to 29 years [2][8]. - The development of this vaccine is part of the Translational Science Hub, a collaboration involving the Queensland Government, Griffith University, and the University of Queensland, connecting researchers in Australia with Sanofi scientists [5]. Group 2: Public Health Impact - Chlamydia is a common bacterial infection with serious long-term health consequences, including infertility and pregnancy complications, affecting 129 million adults globally in 2020, particularly among adolescents and young adults [3][4]. - Over 80% of chlamydia cases are asymptomatic, leading to untreated infections and unintentional transmission, underscoring the urgent need for a vaccine to prevent rising infection rates [4]. Group 3: Company Overview - Sanofi is an innovative global healthcare company focused on improving lives through scientific advancements, providing life-changing treatments and vaccines while emphasizing sustainability and social responsibility [6].

Availability of the Q1 2025 Aide mémoire Paris, France – March 24, 2025. Sanofi announced today that its Q1 2025 Aide mémoire is available on the "Investors" page of the company's website: First quarter 2025 (sanofi.com) As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items and exclusivity losses as well as the foreign currency impact and share count. Sanofi's first quarter ...

One stock that might be an intriguing choice for investors right now is Banco Santander (SAN) . This is because this security in the Banks - Foreign space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Finance spac ...

Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Dren Bio deep B-cell depleter program has the potential to reset the immune systemAcquisition underpins path for Sanofi becoming leading immunology companySanofi to pay $600 million up front Paris, March 20, 2025. Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targete ...